Kornimate/medical-research-clean huggingface dataset:
retrospective evaluation of athens complete health improvement program (chip) database

Conditions: Cardiovascular Diseases; Diabetes Mellitus; Hypertension; Dyslipidemias; Overweight and Obesity

Summary: data from participants in athens chip classes from may 2011 to present will be analyzed to evaluate the differences in outcomes based on: 1) gender, 2) age, 3) whether a household member participated in the class with them. participants had health screens before and after completing the class. the data from the health screens that will be utilized for comparison will include: body mass index (bmi), blood pressure, and fasting blood sugar and lipid levels.

identified data will be provided to the pi from live healthy appalachia/chip on a flash drive. this data will be password protected by the research team. the data will consist of two different databases, 1) identifiers with health screen results, 2) identifiers with demographics (age, gender, household member in class). the researchers need data from both databases for this study. each participant has been assigned a unique participant number by chip. the databases will be combined by the research team, allowing the demographics to be matched to the biomarkers. the unique chip identifier will be maintained as a participant id, while all other identifying data will then be deleted from the database. the data will then be analyzed for relationships by a statistician.

Eligibility criteria:
inclusion criteria: * enrolled in the complete health improvement program * signed the chip request to participate consent form, which includes the statement: "i understand that my test results are confidential but may be used for statistical analysis and group summaries." * completed both health screens exclusion criteria: none

Keywords: nutrition exercise stress gender age community support cardiovascular disease diabetes hypertension dyslipidemia cholesterol overweight obesity lifestyle
a 1-year program to treat children who have been victims of child sexual abuse

Conditions: Sexual Abuse of Child (If Focus of Attention is on Victim)

Summary: our goal in this study is examine if a program designed to decrease the severity of post-traumatic stress disorder symptoms in sexually abused children between the ages of 8-12 was effective.


Eligibility criteria:
inclusion criteria: * history of sexual abuse * aged 8 - 12 years * developmentally able to be on-site in a "camp-like" treatment facility for 3 weeks with their parent/guardian (or without if family is not available to join the child at the be brave ranch) * able to perform skills of daily living for self care * good physical health exclusion criteria: * severe mental health issues including (but not limited to): * recent suicide attempt * history of psychosis * history of significant self-harm * history of homicidal thoughts or actions * history of violent behaviours sufficient to be considered a threat to others * acute eating disorder. * significant risk of absconding, or history of absconding * serious behavioural problems * significant use of drugs or alcohol * history of sexual violence or sexual behaviour towards others * any significant interaction with the justice system or police * cognitive impairment that would interfere with treatment benefits * medical conditions that are not stable * severe medical conditions

Keywords: child sexual abuse csa treatment prevention ptsd post traumatic stress disorder depression anxiety quality of life attachment cognitive behavioural therapy group therapy
platelet rich plasma (prp) one-shot injection for supraspinatus tendinosis

Conditions: Supraspinatus Tendinitis

Summary: it was conducted a prospective study with a series of 50 patients treated with prp one-shot injection in patient affected by supraspinatus tendinosis. one independent observer performed clinical and functional evaluations at t0 (recruitment), t1 (one month after the injection), t2 (three months after the last injection) and t3 (six months after the last injection). constant score, the disabilites of the arm,shoulder and hand score (dash) and visual analogue scale (vas) were administered at each evaluation.


Eligibility criteria:
inclusion criteria: * age \> 18 years old; * supraspinatus tendinosis detected by mri. exclusion criteria: * supraspinatus rupture; * previous shoulder surgery; * rotator cuff tears secondary to fracture; * hemoglobin \<7 g/dl or platelets \< 30,000 microl; * active infection; * pregnant patients; * patients with hematologic and oncologic diseases.

Keywords: supraspinatus tendinosis; prp; shoulder;
study of extracellular vesicles (ev) in patients undergoing car-t cell therapies

Conditions: CAR-T Cell Therapy; Extracellular Vesicles

Summary: patients with refractory/relapse hematologic oncology disease may benefit from innovative therapy such as car-t cells. factors strongly predictive of outcome and response are unknown. extracellular vesicles are recognized as a mode of intercellular communication and are reminiscent of the cell of origin. they are currently candidates to be biomarkers for this biomarker of phenomena occurring in tissues. the working hypothesis is that they may be predictive of outcome and toxicity, as some preliminary data have suggested. therefore, the aim of the study concerns i dentification of potential car-ev biomarkers associated with neurological toxicity after infusion of car-t cells.


Eligibility criteria:
inclusion criteria: * patients affeccted by any hematological malignancies (r/r b cell lymphoma, b cell acute leukemia and multiple myeloma) undergoing (or whit indication to) car-t cell infusion with a car-t cell product; * age: 18 years or greater; * obtained written consent to the study participation. exclusion criteria: * none
esophageal atresia: metaplasia, barrett

Conditions: Gastroesophageal Reflux; Esophagus, Barrett

Summary: the frequency of barrett's esophagus (be) has increased in adults in the last decades, but be is rare in children. esophageal atresia (ea), the most common congenital anomaly affecting the esophagus, predisposes the patient to severe and prolonged gastroesophageal reflux disease. because gastroesophageal reflux disease plays a major role in the development of be by causing repeated mucosal damage, development of be is a concern even in children and young adults in this specific population. the aim of this study is to assess the prevalence of be (gastric and/or intestinal metaplasia) in a population of adolescents/young adults who had been treated for ea in early infancy. all eligible patients received upper gastrointestinal endoscopy under general anesthesia with standardized esophageal staged biopsies. histological suspicion of metaplasia was confirmed centrally.


Eligibility criteria:
inclusion criteria: * medical history of esophageal atresia (all types, ladd's classification) exclusion criteria: * no medical history of esophageal atresia * non acceptance to participate from the patient and/or his parents * esophageal atresia treated with esophageal replacement (e.g., coloplasty, gastric transposition)

Keywords: gastroesophageal reflux barrett esophagus
red flags for cardiac examination for early detection of congenital heart disease

Conditions: Congenital Heart Disease

Summary: the study done to identify the relation between the presence of abnormal clinical cardiac findings and the echocardiographic findings in newborn infants.

a full history will be taken, complete general systemic and cardiac examination will be done. all patients with abnormal physical cardiac examination in the neonatal period (≤ 28 days of age) according to the inclusion criteria will have echocardiographic examination.

Eligibility criteria:
inclusion criteria: * • abnormal heart rate (\< 90/min or \< 160 per min ) * comfortable tachypnea ( rr \> 60/min without other manifestations of respiratory distress) * abnormal heart sounds (muffled, accentuated, single ) * abnormal precordial activity * murmur: ( ≥ grade 3 intenisty, holosystolic timing, maximum intensity at upper left sternal border or with upright positing, diastolic murmur, harsh or blowing quality ) * abnormal oxygen saturation \ 3% difference in extremities. * blood pressure gradient \>10 mmhg higher in arms \>10 mmhg lower in legs * abnormal femoral pulses * weakened pulses * absent pulses * hepatomegaly * family history of cardiac disease exclusion criteria: * newborns with disorders affecting the heart as anemia, septicemia, respiratory disorders as respiratory distress syndrome, pneumonia, hypoplastic lung, renal impairment, hypertension, metabolic disease, syndromatic chf
second-line treatments for anovulatory infertility in pcos patients

Conditions: Polycystic Ovary Syndrome; Infertility; Anovulation

Summary: to date, it is still unclear the potential role of laparoscopic ovarian diathermy (lod) in the management of polycystic ovary syndrome (pcos)-related anovulatory infertility. metformin administration, alone or combined with clomiphene citrate (cc), has shown to be an effective and attractive second-line treatment for ovulation induction in women with polycystic ovary syndrome (pcos) after failure of cc treatment. the aim of the present study will be to compare in a randomized controlled fashion the efficacy of lod with metformin plus cc administration in the treatment of the cc-resistant pcos patients.

a total of 50 primary infertile anovulatory pcos patients with documented cc-resistance will be enrolled and randomized into two groups of treatment of 25 subjects each. group a will undergo diagnostic laparoscopy followed by metformin plus cc, whereas group b will undergo lod followed by observation. anovulatory patients will receive im progesterone. the treatment will be of six months followed by nine-month of observation for pregnant patients. the incidence of spontaneous menses, and the pregnancy, abortion, and live-birth rates will be recorded.

Eligibility criteria:
inclusion criteria: * pcos * clomiphene citrate-resistance * anovulation * infertility exclusion criteria: * age \ 35 years * body mass index \>35 * neoplastic, metabolic, endocrine, hepatic, renal, and cardiovascular disorders or other concurrent medical illnesses * current or previous use of oral contraceptives, glucocorticoids, antiandrogens, ovulation induction agents, antidiabetic and anti-obesity drugs or other drugs affecting hormone levels, carbohydrate metabolism, or appetite * pelvic diseases * previous pelvic surgery * suspected peritoneal factor infertility/subfertility * tubal or male factor infertility or sub-fertility

Keywords: anovulation clomiphene citrate fertility metformin ovulation induction pcos sterility treatment clomiphene citrate-resistance
effect of the cardio first angle device on cpr outcomes

Conditions: Cardiopulmonary Arrest

Summary: the investigators conducted a randomized, controlled, single-blinded study of patients undergoing cpr for cardiac arrest in the mixed medical-surgical icus of four academic teaching hospitals in tehran, iran from june 1 to october 31, 2014. patients were randomized to receive cpr with either standard manual compression, or compression with real-time audiovisual feedback using the cardio first angel™ device.

the investigators sought to determine if the addition of a cpr feedback device to routine manual cpr would impact the quality and consistency of chest compression and patient survival. we conducted a randomized, controlled, single-blinded study of patients undergoing cpr for cardiac arrest in the mixed medical-surgical icus of four academic teaching hospitals. patients were randomized to receive either standard manual cpr or cpr using the cardio first angel™ (cfa; inotech, nubberg, germany) feedback device. recorded variables included return of spontaneous circulation, adherence to cpr guidelines and quality of cpr, nurse satisfaction and cpr associated morbidity.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * admitted to the intensive care unit (icu) * full-code status * informed consent was obtained from the patient, legal guardian, or healthcare surrogate upon icu admission (prior to cardiac arrest event) exclusion criteria: * patients with any limitation of code status including but not limited to "no code" or"do not resuscitate" (dnr) and"do not intubate" (dni), were excluded from study participation

Keywords: cpr cardio first angle clinical trial
quest sound recover (sr2) vs. venture sr2

Conditions: Hearing Loss

Summary: goal of this study is to determine the benefit of an improved feature on a new hearing aid platform. to investigate the improvements of this feature is compared on a new and older hearing aid platform. the obtained results will be used for future improvement for this feature. this feature should improve the speech understanding and speech recognition of the hearing aid user.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature (appendix informed consent form) * ability to fill in a question conscientious * healthy outer ear (w/o previous surgical procedures) * sensorineural symmetric hearing loss (hl) * n4 to n7 (degree of hl) exclusion criteria: * contraindications to the md in this study, e.g. known hypersensitivity or allergy to the investigational product, * limited mobility and not in the position to attend weekly appointments * limited ability to describe listening impressions/experiences and the use of the hearing aid * inability to produce a reliable hearing test result when pure tone audiometry is attempted by the audiologist * massively limited dexterity * known psychological problems * central hearing problems
evaluate the immunogenicity & safety of gsk biologicals' hpv vaccine in female subjects aged 10-14 years

Conditions: Infections, Papillomavirus

Summary: human papillomavirus infection has clearly been recognized as the cause of cervical cancer. indeed, the infection of the cervix by certain oncogenic types of hpv, if not cleared , can lead over time to cervical cancer in women . this study will evaluate the immunogenicity and the safety of the hpv vaccine in female subjects aged 10 - 14 years in korea.

study participants will receive either hpv or hepatitis a vaccine, study duration will last for 7 months and involve a total of 4 visits.

Eligibility criteria:
inclusion criteria: * a female subject between, and including, 10 and 14 years of age at the time of the first vaccination. * written informed assent from the subject and informed consent from the parent or guardian of the subject should be obtained prior to enrolment. * subjects must have a negative urine pregnancy test. * healthy subject before entering the study as established by medical history and clinical examination. * subject must be of non-childbearing potential. exclusion criteria: * pregnant or breastfeeding. * previous vaccination against hpv. * known acute or chronic, clinically significant neurologic, hepatic or renal functional abnormality * history of chronic condition(s) requiring treatment such as cancer, chronic hepatic or kidney disease(s), diabetes, or autoimmune disease."
a new quantitative fecal immunochemical test in detecting colorectal advanced adenoma

Conditions: Colorectal Adenoma; Colorectal Neoplasm; Colorectal Cancer

Summary: early detecting and removing of colorectal advanced adenomas can reduce incidence of colorectal cancer. because of the less bleeding of advanced adenomas, the sensitivity of existing quantitative fecal immunochemical test (qfit) is unsatisfying. a new technology qfit, which have a higher sensitivity in extremely low concentration of hemoglobin compared with existing commercially available qfit, is developed and this study will prove the high diagnostic accuracy in detecting colorectal advanced adenoma.

colorectal cancer accounts for approximately 10% of all annually diagnosed cancers and cancer-related deaths worldwide. with progress of developing countries, it is predicted that the incidence of colorectal cancer worldwide will increase to 2.5 million new cases in 2035. the majority of colorectal cancer is thought to arise from precancerous lesions through the adenoma-carcinoma pathway. detecting and removing of colorectal advanced adenomas can reduce incidence of colorectal cancer. although colonoscopy is currently considered the most effective method for detecting advanced adenomas, individuals may be reluctant to undergo colonoscopy due to the uncomfortable feeling and the relatively high cost of colonoscopy. conversely, stool tests are relatively cheap and more readily accepted. annual fecal immunochemical test (fit), one of the preferred methods of colorectal cancer screening, is economic and easy to use. however, the existing commercially available qfit is insufficiently sensitive to the minor hemorrhage of advanced adenomas, and the sensitivity is about only 27% to 47%. to improve diagnostic accuracy in detecting colorectal advanced adenoma, an improved technology of qfit, which have a higher sensitivity in extremely low concentration of hemoglobin in stool compared with existing commercially available qfit, is developed. the investigators design this research to prove the diagnostic accuracy of the new qfit in detecting colorectal advanced adenoma.

Eligibility criteria:
inclusion criteria: * 50-75 years old people; * people sign an "informed consent form" exclusion criteria: * people with history of surgery in any part of the large bowel; * people with history of colorectal cancer; * people with history of other diseases that may produce fecal blood, such as active diverticulitis, inflammatory bowel disease, ischemic enteritis, vascular malformation of intestine, intestinal tuberculosis or non-hodgkin's lymphoma involving digestive tract; * people with symptoms including visible rectal bleeding, hematuria, hemorrhoid bleeds, severe and acute diarrhea and 7th type stool (bristol feces score); * people are in pregnancy, lactation or menstrual phase; * people with severe congestive heart failure or other sever disease cause cannot tolerate colonoscopy.

Keywords: colorectal adenoma colorectal neoplasms occult bleeding quantitative fecal immunochemical test colorectal cancer
platelet rich plasma (prp) as terapeutical option in erectil disfunction (de)

Conditions: Erectile Dysfunction Due to General Medical Condition; Erectile Dysfunction Following Radical Prostatectomy; Erectile Dysfunction Associated With Type 2 Diabetes Mellitus; Erectile Dysfunctions

Summary: patients are randomized into 2 groups (a and b), subsequently group a is subjected to a cycle of 6 weekly injections of 3 ml of autologous prp while group b is subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg. after 4 (four) weeks the groups will be crossed, so group a will be subjected to 6 weekly injections of 1 ml of caverject (alprostadil) 20 mcg while group b will be subjected to a cycle of 6 weekly injections of 3 ml of autologous prp.


Eligibility criteria:
inclusion criteria: * moderate to severe erectile dysfunction (iief-5 score below 17) * patients previously treated with first- and second-line therapies for ed * patients who have undergone radical pelvic surgery with nerve sparing * good pharmacological blood pressure control * well-controlled diabetes on medication * current or former smokers * good renal function even with the use of medications * well-controlled hypertriglyceridemia and/or hypercholesterolemia even with the use of medications * bmi less than or equal to 35 * normal levels of fsh, lh, prl, total testosterone, and tsh exclusion criteria: * patients on antidepressant, anxiolytic, sedative, or antipsychotic medications. * consumers of more than 500 g of alcohol per day. * bmi greater than 35 * altered levels of fsh, lh, prl, total testosterone, and tsh.
can methylnaltrexone safely treat opioid related constipation in the emergency department?

Conditions: Colonic Inertia

Summary: the investigators want to prove that people without advanced cancer who are taking opioid medications (for problems like back pain) can receive methylnaltrexone (mntx) safely. since the fda has only approved mntx for advanced cancer patients, the investigators' research is investigating how mntx can work for non-cancer patients. this research is being conducted to prove that mntx can work for non-cancer patients with opioid related constipation.


Eligibility criteria:
inclusion criteria 1. age 18 and greater 2. clinical diagnosis of constipation 3. any patients that report taking an opioid analgesic for greater than two (2) weeks (eg known oncology patients and chronic pain syndrome patients, including those with low back pain or sciatica) 4. patients must have previously tried a stable laxative regiment for at least three (3) days prior to study entry. 5. all patients will have a flat and upright abdominal x-ray, and chest x-ray to exclude gastrointestinal (gi) obstruction. any patients who have radiographic evidence of gi obstruction will need a ct scan of the abdomen to exclude gi obstruction prior to study enrollment. 6. females of childbearing potential must have a negative pregnancy test and must be encouraged to use appropriate birth control for a period after the study. 7. willing to comply with study instructions and sign an informed consent exclusion criteria: 1. pregnancy or lactation 2. recent surgery within six (6) weeks of the emergency department visit 3. opioid withdrawal syndrome as determined by clinical judgment. 4. patients with previous history of diabetic gastroparesis. 5. any patient who has known or suspected gastrointestinal obstruction 6. any patients with creatinine clearance ≤ 30 ml/min 7. constipation for which other medical causes cannot be excluded such as anticholinergic medications, botulinum toxin, or botulism. 8. any patient with sbp ≤ 80 mmhg or dbp ≤ 45 mmhg or unstable vital signs. 9. inability to understand or follow the instructions associated with the clinical study as determined by clinical judgment. 10. a known history of substance abuse on methadone maintenance therapy \> 12 months 11. allergy or contraindication to use of methylnaltrexone 12. prior enrollment in study

Keywords: constipation opioid
study of hl-085 plus docetaxel in patients with kras mutant nsclc

Conditions: Nsclc

Summary: this is a phase i, open label, dose escalation study to evaluate tolerability, safety , pharmacokinetics and efficacy in patients with kras mutant nsclc by using hl-085 and docetaxel.


Eligibility criteria:
inclusion criteria: 1. kras mutation nsclc. 2. one measurable lesion as defined by recist 1.1 criteria for solid tumors. 3. chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study treatment. 4. surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the study treatment. 5. ecog performance status of 0-1. 6. life expectancy ≥ 3 months. 7. ability to take the medicine orally. 8. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. hypersensitivity to study drug ingredients or their analogues. 2. prior therapy with mek-inhibitor. 3. receiving any other anti-cancer therapy at the same time . 4. active central nervous system (cns) lesion. 5. bleeding symptoms at grade 3 within 4 weeks prior to starting study treatment. 6. ecg qtcb≥480msec in screening, or history of congenital long qt syndrome； 7. uncontrolled concomitant diseases or infectious diseases. 8. retinal diseases (retinal vein occlusion (rvo) or retinal pigment epithelial detachment (rped) , et al.). 9. history of hiv,hcv,hbv infection. 10. interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis will be excluded. 11. serum hcg test is positive. 12. other conditions that increase the risk of study and influence the result.